Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 162 participants.

Also called NCT03574363

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 162 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03574363
Other papers using this trial's data
  • Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study Hypertension (Dallas, Tex. : 1979), 2021-07 DOI, PubMed 33966452, PMC8189259 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03574363. Randomized; triple masking; primary purpose treatment. Start 2018-04-25 (actual); primary completion 2020-08-05 (actual). Results posted on 2024-03-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease
Acronym
BLOCKCKD
Condition
Chronic Kidney Diseases
Condition
Hypertension
Intervention (Drug)
KBP-5074 0.25 mg tablet
Intervention (Drug)
KBP-5074 0.5 mg tablet
Lead sponsor
KBP Biosciences (class: industry)
Collaborator
Worldwide Clinical Trials (class: other)

Record details

Record id
cardio:ct-nct03574363
Content hash
4383ff9e0ede49f4ac6dfb1cc6a00cb2b17367e8b019a8d3b2a2513f4cfe714e